Fulcrum Therapeutics (FULC) Current Deferred Revenue (2019 - 2023)

Fulcrum Therapeutics (FULC) has reported Current Deferred Revenue for 5 consecutive years, with $600000.0 the latest figure, recorded in Q3 2023.

• In Q3 2023, Current Deferred Revenue rose 50.0% year-over-year to $600000.0; the TTM figure through Sep 2023 stood at $600000.0 (up 50.0% YoY), while the FY2022 annual figure was $900000.0, down 71.88% from the prior year.
• Current Deferred Revenue advanced to $600000.0 in Q3 2023 per FULC's latest filing, from $513000.0 in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $14.9 million in Q4 2020 and bottomed at $400000.0 in Q3 2022.
• Historically, Current Deferred Revenue has averaged $4.1 million across 5 years, with a median of $2.0 million in 2021.
• Annual changes were most pronounced in 2020 — Current Deferred Revenue jumped 273.78% — and 2022, when it sank 89.28%.
• Fulcrum Therapeutics' Current Deferred Revenue stood at $4.0 million in 2019, then surged by 273.78% to $14.9 million in 2020, then plunged by 78.54% to $3.2 million in 2021, then plunged by 71.88% to $900000.0 in 2022, then plunged by 33.33% to $600000.0 in 2023.
• Business Quant data shows FULC's Current Deferred Revenue at $600000.0 in Q3 2023, $513000.0 in Q2 2023, and $737000.0 in Q1 2023.